Press Release

Kiadis announces new data related to its K-NK cell therapy platform presented today at the ISCT Annual Meeting

May 28, 2020 at 2:35 AM EDT
  • Data presented demonstrates improved ex vivo PM21 expansion of NK cells when pre-activated with cytokines.

Amsterdam, The Netherlands, May 28, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, announces that new data related to its K-NK cell therapy platform will be presented today at the International Society of Cell & Gene Therapy (ISCT) virtual annual meeting. Poster #228, from the lab of Alicja Copik, Ph.D., at the University of Central Florida, will present data that shows how cytokine pre-activation enhances Kiadis’ PM21-particle driven NK cell expansion.

Dr. Copik’s group performed preclinical research to understand how both the expansion and the activity of ex vivo expanded NK cells can be further enhanced by coupling the PM21 expansion process with cytokine pre-activation prior to the expansion. This results in high-scale expansion of NK cells with a “memory-like” phenotype that can be re-activated upon detection of stimuli, resulting in a more potent response upon tumor detection. Other methods for producing NK cells with “memory-like” features have been developed and applied clinically, but cell yields were low and manufacturing processes were not amenable to scalable, commercial development.

Results presented as part of Dr. Copik’s poster at ISCT demonstrate that high-scale expansion of “memory-like” NK cells can be obtained with a combined pre-activation with cytokines followed by expansion with Kiadis’ PM21-platform. NK cells from healthy donor-derived peripheral blood mononuclear cell (PBMCs) were stimulated overnight with IL-12, IL-18 and IL-15 and then expanded with PM21 particles. The new methodology resulted in a significantly further increased expansion of NK cells than with PM21 alone. Also, the NK cells that were preactivated produced even larger amounts of IFNγ and were very responsive to activation by K562 tumor cells or cytokines.

In addition, receptor expression was similar for both cytokine preactivated NK and PM21 activated NK cells and demonstrated that both are in a highly activated state as compared to IL-2 activated NK cells. In vitro and in vivo data are also presented that confirm their anti-leukemic effects.

In summary, pre-activation with IL-12, IL-18 and IL-15 followed by PM21 particle expansion leads to significantly further increases of NK cells. Such NK cells have further enhanced IFNγ production upon stimulation with cytokines or tumor cells compared to PM21-NK cells without pre-activation, to yield a unique NK cell phenotype with a hyper-functional phenotype and potent therapeutic potential.

Robert Friesen, Chief Scientific Officer of Kiadis, commented, “The data presented today demonstrate the Kiadis platform can be further improved upon and we are excited to potentially incorporate this methodology into our manufacturing options to possibly attain even higher yields of more potent therapeutic NK cells that would further increase accessibility to patients in urgent need of novel therapeutic options.”

The poster is available at www.kiadis.com.

Kiadis Contacts:

Kiadis:
Maryann Cimino, Sr. Manager, Corporate Affairs
Tel: +1 (617) 710-7305
m.cimino@kiadis.com

 
Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 950 9144
David Brilleslijper (Amsterdam)
Tel: +31 610 942 514
kiadis@optimumcomms.com

Dutch Translation/Nederlandse vertaling

Kiadis Pharma N.V. (‘Kiadis’), een biofarmaceutisch bedrijf gericht op onderzoek in de klinische fase, zal nieuwe informatie over het K-NK-celtherapieplatform presenteren op het jaarlijkse ISCT-congres (International Society of Cell & Gene Therapy). Op poster #228 van het laboratorium van Alicja Copik, Ph.D., werkzaam bij de University of Central Florida, zal informatie worden gepresenteerd over hoe de cytokine-preactivering de op PM21 gebaseerde NK-celexpansie van Kiadis verbetert.

De groep van Dr. Copik voerde preklinisch onderzoek uit om inzicht te krijgen in hoe het PM21-expansieproces vóór expansie gecombineerd kan worden met cytokine-preactivering om zowel de expansie als de activiteit van ex vivo geëxpandeerde NK-cellen te verbeteren. Dit resulteert in een grootschalige expansie van NK-cellen met een uniek fenotype dat gereactiveerd kan worden bij detectie van stimuli. Hierdoor is een krachtigere respons mogelijk bij tumordetectie. Er werden al andere klinische methoden ontwikkeld en toegepast om NK-cellen te produceren met cytokine-preactivering, maar daarbij was de celopbrengst laag en waren de productieprocessen niet geschikt voor schaalbare, commerciële toepassingen.

De resultaten die op het ISCT-congres worden getoond op de poster van Dr. Copik tonen aan dat een grootschalige expansie van unieke NK-cellen mogelijk is door een combinatie van cytokine-preactivering gevolgd door expansie met het PM21-platform van Kiadis. NK-cellen afkomstig van perifere mononucleaire bloedcellen (PBMC’s) van een gezonde donor werden kort gestimuleerd met IL-12, IL-18 en IL-15 en vervolgens geëxpandeerd met PM21-deeltjes. De nieuwe methodologie resulteerde in een significant verder vergrote toename van NK-cellen dan wanneer alleen PM21 werd toegepast. De NK-cellen die vooraf werden geactiveerd, produceerden bovendien grote hoeveelheden IFNγ en reageerden zeer goed op activering door K562-tumorcellen of cytokines.

Daarnaast was de receptorexpressie van met cytokine gepreactiveerde NK-cellen vergelijkbaar met PM21-geactiveerde NK-cellen. Beide varianten bevinden zich in een zeer geactiveerde toestand in vergelijking met IL-2-geactiveerde NK-cellen. Er worden ook in-vitro- en in-vivogegevens getoond die de antileukemische werking van de NK cellen bevestigen.

Kortom, preactivering met IL-12, IL-18 en IL-15 gevolgd door PM21-expansie leidt tot een significant hogere expansie van NK-cellen. De IFNγ-productie bij stimulatie met cytokines of tumorcellen is bij dergelijke NK-cellen verder verbeterd dan wanneer enkel PM21-deeltjes worden toegepast zonder preactivering. Dit resulteert in een uniek, hyperfunctioneel fenotype voor NK-cellen met een groot therapeutisch potentieel.

Robert Friesen, Chief Scientific Officer bij Kiadis, zei: “De informatie die we vandaag hebben gepresenteerd toont aan dat het Kiadis-platform nog verder kan worden verbeterd. We zijn verheugd om deze methodologie mogelijk toe te passen in onze productiemethoden. Dit kan in betere therapeutische NK-cellen met een hogere opbrengst resulteren, waardoor we meer patiënten met een dringende behoefte aan nieuwe therapeutische opties kunnen helpen.”

De poster is beschikbaar op www.kiadis.com.

Dit persbericht vormt een vertaling van het gepubliceerde Engelstalige persbericht. Bij eventuele verschillen is de tekst van het Engelstalige persbericht altijd bepalend.

About Kiadis’ K-NK-Cell Therapies
Kiadis’ NK-cell programs consist of off-the-shelf and haplo donor cell therapy products for the treatment of liquid and solid tumors as adjunctive and stand-alone therapies. 

The Company’s NK-cell PM21 particle technology enables improved ex vivo expansion and activation of anti-cancer cytotoxic NK-cells supporting multiple high-dose infusions. Kiadis’ proprietary off-the-shelf NK-cell platform is based on NK-cells from unique universal donors. The Kiadis off-the-shelf K-NK platform can make NK-cell therapy product rapidly and economically available for a broad patient population across a potentially wide range of indications.

Kiadis is clinically developing K-NK003 for the treatment of relapse/refractory acute myeloid leukemia. The Company is also developing K-NK002, which is administered as an adjunctive immunotherapeutic on top of HSCT and provides functional, mature and potent NK-cells from a haploidentical family member. In addition, the Company has pre-clinical programs evaluating NK-cell therapy for the treatment of solid tumors. 

About Kiadis
Founded in 1997, Kiadis is building a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with life-threatening diseases. With headquarters in Amsterdam, the Netherlands, and offices and activities across the United States, Kiadis is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.

Kiadis is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at www.kiadis.com.

Forward Looking Statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis’ or, as appropriate, Kiadis’ officers’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performance, achievements or events to differ materially from those expressed, anticipated or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance, achievements or results to differ significantly from any anticipated or implied development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or projections, or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the anticipated or implied developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

DISCLAIMER – IMPORTANT

THE MATERIALS YOU ARE SEEKING TO ACCESS ARE BEING MADE AVAILABLE ON THIS WEBPAGE BY KIADIS PHARMA N.V. IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY. THE MATERIALS CONTAINED HEREIN ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR DIRECTED AT OR ACCESSIBLE BY PERSONS LOCATED IN AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
.

Please read this notice carefully - it applies to all persons who view this webpage. Please note that the disclaimer set out below may be altered or updated. You should read it in full each time you visit the site.

Non-Dutch persons
Viewing the materials contained herein may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to access such materials. Any person resident outside the Netherlands who wishes to access these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so.

In particular, unless otherwise determined by Kiadis Pharma N.V. and permitted by applicable law and regulation, it is not intended that any offering by Kiadis Pharma N.V. of the securities mentioned in such materials (the "Securities") would be made, or any documentation be sent, directly or indirectly, in or into Australia, Canada, Japan, South Africa or the United States.

The materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for the Securities in any jurisdiction or jurisdictions in which such offers or sales are unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

The offer and sale of the Securities has not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered, sold, resold, taken up, exercised, renounced, transferred or delivered, directly or indirectly, within the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act. No public offering of the Securities is being made in the United States.

The Securities will not be registered under or offered in compliance with applicable securities laws of any state, province, territory, county or jurisdiction of Australia, Canada, Japan or South Africa. Accordingly, unless an exemption under the relevant securities law is applicable, any such securities may not be offered, sold, resold, taken up, exercised, renounced, transferred or delivered, directly or indirectly, in or into Australia, Canada, Japan, South Africa or any other jurisdiction if to do so would constitute a violation of the relevant laws of, or require registration thereof in, such jurisdiction.

If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

Basis of access
Access to these materials is being made available on this webpage by Kiadis Pharma N.V. in good faith and for information purposes only. Any person seeking access to this webpage represents and warrants to Kiadis Pharma N.V. that they are doing so for information purposes only.

None of the materials made available on this website constitutes an offer to sell, an invitation to induce an offer or the solicitation of an offer to acquire, securities in Kiadis Pharma N.V. and cannot be relied upon for any investment contract or decision. Further, such materials do not constitute a recommendation by Kiadis Pharma N.V. or any other party to sell or buy securities in Kiadis Pharma N.V.

Unless otherwise determined by Kiadis Pharma N.V. and permitted by applicable law and regulation, copies of the contents of the following pages (including documents posted thereon) are not being, and must not be, released or otherwise forwarded, distributed or sent in or into Australia, Canada, Japan, South Africa, the United States or any other jurisdictions where their extension or availability (and/or any transaction contemplated thereby) would breach any applicable law, and persons receiving such documents (including custodians, nominees and trustees) must not distribute or send them in, into or from Australia, Canada, Japan, South Africa, the United States or any other jurisdiction where to do so would breach any applicable law.

Confirmation of understanding and acceptance of disclaimer
I certify that I am not located or resident in, nor is the partnership or corporation on whose behalf I am accessing the website organised or incorporated under the laws of, Australia, Canada, Japan, South Africa or the United States or any other jurisdiction where the release, publication or distribution of these materials would be unlawful.

I will not transmit or otherwise send any materials contained in this website to any person located or resident in (or organised or incorporated under the laws of) Australia, Canada, Japan, South Africa or the United States.

I have read and understood the disclaimer set out above and agree to be bound by its terms.

I confirm that I am permitted under applicable law and regulation to proceed to the electronic versions of these materials and receive information of the kind contained in this website.

Agree Disagree